Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234220 | 0.82 | ACACB (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL31234430 | 0.74 | NAMPT (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL31234264 | 0.74 | NAMPT (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL27228926 | 0.73 | HMOX1 (0.35) | MAPTNAMPT | |
| SCHEMBL26988825 | 0.72 | BTK (0.42) | PIK3CDPIK3CANAMPTJAK2JAK1 | |
| SCHEMBL27115842 | 0.72 | BTK (0.42) | PIK3CDPIK3CANAMPTJAK2JAK1 | |
| SCHEMBL26907230 | 0.72 | BTK (0.42) | PIK3CDPIK3CANAMPTJAK2JAK1 | |
| SCHEMBL27229005 | 0.71 | MAPT (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL27232182 | 0.71 | MAPT (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL21193560 | 0.70 | GRIN1 (0.47) | NAMPTL3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 121/4885PIK3CA 40/4885PIK3CB 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.